WO2000012047A3 - Enhancement of return to independent living status with a growth hormone secretagogue - Google Patents
Enhancement of return to independent living status with a growth hormone secretagogue Download PDFInfo
- Publication number
- WO2000012047A3 WO2000012047A3 PCT/US1999/019996 US9919996W WO0012047A3 WO 2000012047 A3 WO2000012047 A3 WO 2000012047A3 US 9919996 W US9919996 W US 9919996W WO 0012047 A3 WO0012047 A3 WO 0012047A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- return
- growth hormone
- enhancement
- hormone secretagogue
- independent living
- Prior art date
Links
- 102100033367 Appetite-regulating hormone Human genes 0.000 title abstract 2
- 101710111255 Appetite-regulating hormone Proteins 0.000 title abstract 2
- 239000003324 growth hormone secretagogue Substances 0.000 title abstract 2
- 206010020100 Hip fracture Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000571019A JP2002525274A (en) | 1998-09-02 | 1999-08-31 | Promotion of return to independent living condition by growth hormone secretagogue |
CA002341649A CA2341649A1 (en) | 1998-09-02 | 1999-08-31 | Enhancement of return to independent living status with a growth hormone secretagogue |
EP99948091A EP1156808A2 (en) | 1998-09-02 | 1999-08-31 | Enhancement of return to independent living status with a growth hormone secretagogue |
AU61332/99A AU6133299A (en) | 1998-09-02 | 1999-08-31 | Enhancement of return to independent living status with a growth hormone secretagogue |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9886998P | 1998-09-02 | 1998-09-02 | |
US60/098,869 | 1998-09-02 | ||
GBGB9823090.7A GB9823090D0 (en) | 1998-10-21 | 1998-10-21 | Enhancement of return to independent living status with a growth hormone secretaogue |
GB9823090.7 | 1998-10-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000012047A2 WO2000012047A2 (en) | 2000-03-09 |
WO2000012047A3 true WO2000012047A3 (en) | 2001-09-27 |
Family
ID=26314549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/019996 WO2000012047A2 (en) | 1998-09-02 | 1999-08-31 | Enhancement of return to independent living status with a growth hormone secretagogue |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1156808A2 (en) |
JP (1) | JP2002525274A (en) |
AU (1) | AU6133299A (en) |
CA (1) | CA2341649A1 (en) |
WO (1) | WO2000012047A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6329342B1 (en) | 1997-08-19 | 2001-12-11 | Eli Lilly And Company | Treatment of congestive heart failure with growth hormone secretagogues |
US6639076B1 (en) | 1998-08-18 | 2003-10-28 | Eli Lilly And Company | Growth hormone secretagogues |
US6828331B1 (en) | 1999-02-19 | 2004-12-07 | Eli Lilly And Company | Growth hormone secretagogues |
EP1313473A2 (en) | 2000-08-30 | 2003-05-28 | Pfizer Products Inc. | Sustained release formulations for growth hormone secretagogues |
EP1192943A3 (en) * | 2000-09-28 | 2002-11-27 | Pfizer Products Inc. | Use of growth hormone secretagogues in conjunction with physical exercise |
CU23157A1 (en) | 2001-01-03 | 2006-07-18 | Ct Ingenieria Genetica Biotech | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TISSULAR DANE DUE TO LACK OF BLOOD IRRIGATION ARTERIAL |
US7125840B2 (en) | 2001-10-09 | 2006-10-24 | Eli Lilly And Company | Substituted dipeptides as growth hormone secretagogues |
WO2003087069A2 (en) | 2002-04-09 | 2003-10-23 | Eli Lilly And Company | Dipeptidic growth hormone secretagogues |
WO2005097174A2 (en) * | 2004-04-07 | 2005-10-20 | Gastrotech Pharma A/S | Uses of a combination of ghrelin and somatotropin for the treatment of cachexia |
ES2710665T3 (en) * | 2006-03-15 | 2019-04-26 | Michael O Thorner | Methods for the treatment of sarcopenia with a growth hormone secretagogue |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997021730A1 (en) * | 1995-12-13 | 1997-06-19 | Merck & Co., Inc. | Growth hormone secretagogue receptor family |
WO1997024369A1 (en) * | 1995-12-28 | 1997-07-10 | Pfizer Inc. | Growth-hormone secretagogues |
US5723616A (en) * | 1995-10-27 | 1998-03-03 | Merck & Co., Inc. | Process for the preparation of a growth hormone secretagogue |
US5767124A (en) * | 1995-10-27 | 1998-06-16 | Merck & Co., Inc. | Polymorphic forms of a growth hormone secretagogue |
US5773441A (en) * | 1995-08-21 | 1998-06-30 | Eli Lilly And Company | 2-acylaminopropanamides as growth hormone secretagogues |
-
1999
- 1999-08-31 AU AU61332/99A patent/AU6133299A/en not_active Abandoned
- 1999-08-31 JP JP2000571019A patent/JP2002525274A/en not_active Withdrawn
- 1999-08-31 CA CA002341649A patent/CA2341649A1/en not_active Abandoned
- 1999-08-31 WO PCT/US1999/019996 patent/WO2000012047A2/en not_active Application Discontinuation
- 1999-08-31 EP EP99948091A patent/EP1156808A2/en not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5773441A (en) * | 1995-08-21 | 1998-06-30 | Eli Lilly And Company | 2-acylaminopropanamides as growth hormone secretagogues |
US5723616A (en) * | 1995-10-27 | 1998-03-03 | Merck & Co., Inc. | Process for the preparation of a growth hormone secretagogue |
US5767124A (en) * | 1995-10-27 | 1998-06-16 | Merck & Co., Inc. | Polymorphic forms of a growth hormone secretagogue |
WO1997021730A1 (en) * | 1995-12-13 | 1997-06-19 | Merck & Co., Inc. | Growth hormone secretagogue receptor family |
WO1997024369A1 (en) * | 1995-12-28 | 1997-07-10 | Pfizer Inc. | Growth-hormone secretagogues |
Non-Patent Citations (6)
Title |
---|
DATABASE CA ON STN, CHEM. ABSTR. (COLUMBUS, OHIO, USA); 10 July 1997 (1997-07-10), CARPINO P.A. ET AL.: "Preparation of Nitrogen Heterocyclic Peptide Analogs as Growth-Hormone Secretagogues" * |
DATABASE CA ON STN, CHEM. ABSTR. (COLUMBUS, OHIO, USA); 19 June 1997 (1997-06-19), ARENA J.P. ET AL.: "Growth Hormone Secretagogue Receptor Family and Their cDNA Sequences from Human, Swine and Rat" * |
DATABASE CA ON STN, CHEM. ABSTR. (COLUMBUS, OHIO, USA); 1997, LIEBER R.L. ET AL.: "Growth Hormone Secretagogue Increases Muscle Strength During Remobilization After Canine Hindlimb Immobilization" * |
DATABASE CA ON STN, CHEM. ABSTR. (COLUMBUS, OHIO, USA); 1998, MURPHY M.G. ET AL.: "MK-677, An Orally Active Growth Hormone Secretagogue, Reverses Diet-Induced Catabolism" * |
J. CLIN. ENDOCRINOL. METAB.,, vol. 83, no. 2, 1998, pages 320 - 325 * |
J. ORTHOP. RES.,, vol. 15, no. 4, 1997, pages 519 - 527 * |
Also Published As
Publication number | Publication date |
---|---|
WO2000012047A2 (en) | 2000-03-09 |
EP1156808A2 (en) | 2001-11-28 |
AU6133299A (en) | 2000-03-21 |
CA2341649A1 (en) | 2000-03-09 |
JP2002525274A (en) | 2002-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO924697D0 (en) | SURGICAL IMPLANT AND A PROCEDURE FOR TREATMENT OF SURGICAL IMPLANT | |
EP1121904A3 (en) | Fixation member for treating orthopaedic fractures | |
ZA9711353B (en) | Intramedullary cavity nail for the treatment of fractures of the hip. | |
ZA964816B (en) | Implant for the surgical treatment of a vertebral isthmus fracture. | |
ATE255367T1 (en) | INTEGRAL NAIL SYSTEM FOR FRACTURE HEALING OR BONE LENGTHENING | |
ZA200204327B (en) | Implantable screw for stabilization of a joint or a bone fracture. | |
DE50014411D1 (en) | MEDICAL INSTRUMENT FOR THE DISPOSAL OF TISSUE, BONE CEMENT OR THE SIMILAR IN THE HUMAN OR ANIMAL BODY | |
DE59810425D1 (en) | MARBLE NAIL FOR OPERATING TREATMENT OF FOREARM FRACTURES | |
NO2014010I2 (en) | ||
AU2154700A (en) | Systems for securing sutures, grafts and soft tissue to bone and periosteum | |
WO2004032988A3 (en) | Coupling agents for orthopedic biomaterials | |
AU2001258138A1 (en) | Bone plate for the fixation of fractures of the proximal humerus | |
WO2003084602A3 (en) | Device for stimulating bone growth, especially for the osteosynthesis of bone fragments and/or for fixing bone fractures | |
FR2796545B1 (en) | POLY-AXIAL LINK FOR OSTEOSYNTHESIS SYSTEM, ESPECIALLY FOR THE RACHIS | |
CA2397071A1 (en) | Materials and methods for improved bone tendon bone transplantation | |
DE69811933D1 (en) | SPINAL IMPLANT | |
WO2003013342A3 (en) | Materials and methods for improved bone tendon bone transplantation | |
WO2002040069A3 (en) | Bioactive surgical suture | |
WO2000012047A3 (en) | Enhancement of return to independent living status with a growth hormone secretagogue | |
EP1136045A3 (en) | Prosthesis with securing flange | |
AU3904200A (en) | Bone fracture fixation clip | |
EP0366029A3 (en) | Bone repairing material and artificial bone fixing agent | |
WO2002096324A3 (en) | Bone implant | |
WO2002005718A3 (en) | Suture anchor for attaching a suture to a bone part | |
WO2003022224A3 (en) | Cox-2 function and wound healing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 61332/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2341649 Country of ref document: CA Ref country code: CA Ref document number: 2341649 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 571019 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999948091 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWP | Wipo information: published in national office |
Ref document number: 1999948091 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999948091 Country of ref document: EP |